Pfizer inks peptide deal with Sutro

Sutro Biopharma has landed a multi-year collaboration with Pfizer for the research, development and commercialization of novel peptide-based therapeutics. Financial details of the deal were not disclosed. The company says it's developing new and biosuperior protein therapeutics with better pharmaceutical properties. Sutro recently raised. $36.5 million in a Series C financing. Sutro release